Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women.

The objective was to evaluate the effect of third-generation oral contraceptives on high-sensitivity C-reactive protein (CRP) homocysteine and lipids levels in a population of young fertile nonobese women. Blood markers were evaluated in 277 healthy white women (mean age 23 years and mean body-mass index 21 kg/m2). Seventy-seven oral contraceptive users were compared with 200 non-oral contraceptive users. Progressive cutoffs of high-sensitivity CRP and homocysteine levels were examined. Levels of high-sensitivity CRP posing a high risk of cardiovascular disease (3.0 to less than 10.0 mg/L) were found in 27.3% of oral contraceptive users and in 8.5% of non-oral contraceptive users (odds ratio 4.04; 95% confidence interval [CI] 1.99-8.18). Levels of high-sensitivity CRP at intermediate risk (1.0 to less than 3.0 mg/L) were found in 32.5% of oral contraceptive users and in 11.0% of non-oral contraceptive users (odds ratio 3.89; 95% CI 2.03-7.46). Notably non-oral contraceptive users were 8.65 (95% CI 4.39 -17.1) times as likely to demonstrate a protective level of high-sensitivity CRP (less than 0.5 mg/L) compared with oral contraceptive users. Oral contraceptive use increased serum triglycerides (P less than .001) and total cholesterol P = .001); however high-density lipoprotein not low-density lipoprotein contributed to this increase. A decreased ratio of low-density lipoprotein to high-density lipoprotein cholesterol was observed in oral contraceptive users compared with nonusers (P = .016). Oral contraceptive use did not affect homocysteine levels. Third-generation oral contraceptive use increases low-grade inflammatory status measured by high-sensitivity CRP concentrations. Alteration of inflammatory status in oral contraceptive users could affect the risk of venous thromboembolism cardiovascular disease and other oral contraceptive-associated adverse conditions in young women. (authors)